New combination therapy for cancer cells could soon be a reality

A new cancer therapy using nanoparticles to deliver a combination therapy direct to cancer cells could be on the horizon, thanks to research from the University of East Anglia.

The new therapy, which has been shown to make breast cancer and prostate cancer tumors more sensitive to chemotherapy, is now close to entering clinical trials.

And scientists at UEA's Norwich Medical School have confirmed that it can be mass-produced, making it a viable treatment if proved effective in human trials.

Using nanoparticles to get drugs directly into a tumor is a growing area of cancer research. The technology developed at UEA is the first of its kind to use nanoparticles to deliver two drugs in combination to target cancer cells.

The drugs, already approved for clinical use, are an anti-cancer drug called docetaxel, and fingolimod, a multiple sclerosis drug that makes tumors more sensitive to chemotherapy.

Fingolimod cannot currently be used in cancer treatment because it also suppresses the immune system, leaving patients with dangerously low levels of white blood cells.

And while docetaxel is used to treat many cancers, particularly breast, prostate, stomach, head and neck and some lung cancers, its toxicity can also lead to serious side effects for patients whose tumors are chemo-resistant.

Because the nanoparticles developed by the UEA team can deliver the drugs directly to the tumor site, these risks are vastly reduced. In addition, the targeted approach means less of the drug is needed to kill off the cancer cells.

"So far nobody has been able to find an effective way of using fingolimod in cancer patients because it's so toxic in the blood," explains lead researcher, Dr Dmitry Pshezhetskiy from the Norwich Medical School at UEA.

"We've found a way to use it that solves the toxicity problem, enabling these two drugs to be used in a highly targeted and powerful combination."
The UEA researchers worked with Precision NanoSystems' Formulation Solutions Team who used their NanoAssemblr™ technology to investigate if it was possible to synthesize the different components of the therapy at an industrial scale.

Following successful results on industrial scale production, and a published international patent application, the UEA team is now looking for industrial partners and licensees to move the research towards a phase one clinical trial.

Also included within the nanoparticle package are molecules that will show up on an MRI scan, enabling clinicians to monitor the spread of the particles through the body.

The team has already carried out trials in mice that show the therapy is effective in reducing breast and prostate tumors. These results were published in 2017.

"Significantly, all the components used in the therapy are already cleared for clinical use in Europe and the United States," says Dr Pshezhetskiy. "This paves the way for the next stage of the research, where we'll be preparing the therapy for patient trials."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Precision NanoSystems Inc.. (2019, June 19). New combination therapy for cancer cells could soon be a reality. News-Medical. Retrieved on June 14, 2024 from https://www.news-medical.net/news/20180810/New-combination-therapy-for-cancer-cells-could-soon-be-a-reality.aspx.

  • MLA

    Precision NanoSystems Inc.. "New combination therapy for cancer cells could soon be a reality". News-Medical. 14 June 2024. <https://www.news-medical.net/news/20180810/New-combination-therapy-for-cancer-cells-could-soon-be-a-reality.aspx>.

  • Chicago

    Precision NanoSystems Inc.. "New combination therapy for cancer cells could soon be a reality". News-Medical. https://www.news-medical.net/news/20180810/New-combination-therapy-for-cancer-cells-could-soon-be-a-reality.aspx. (accessed June 14, 2024).

  • Harvard

    Precision NanoSystems Inc.. 2019. New combination therapy for cancer cells could soon be a reality. News-Medical, viewed 14 June 2024, https://www.news-medical.net/news/20180810/New-combination-therapy-for-cancer-cells-could-soon-be-a-reality.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Horizon 2020 program selects Precision NanoSystems’ NanoAssemblr platform to develop RNA medicines